What's Happening?
On September 29, 2026, the President issued Executive Order 14434, titled 'Inaugurating the Era of Super Intelligence.' This Executive Order mandates that executive departments and agencies, including the U.S. Food and Drug Administration (FDA), use the terms
'Super Intelligence' and 'SI' instead of 'Artificial Intelligence' and 'AI' in official correspondence, public communications, websites, reports, policy documents, and other non-statutory documents. This change is effective as of November 16, 2026. The Executive Order defines 'Super Intelligence' and 'SI' as technologies and systems encompassed by the existing definition of 'artificial intelligence' in 15 U.S.C. 9401(3). The FDA will begin incorporating these new terms into newly issued public-facing documents and communications, and will update existing public-facing documents during their next substantive revision and web content on its regular maintenance cycle. However, where a statute or regulation specifically uses 'artificial intelligence' or 'AI,' the FDA will continue to quote and cite those terms as written.
Why It's Important?
This shift in terminology, mandated by Executive Order 14434, signifies a deliberate effort by the executive branch to reframe the public and governmental discourse around advanced technological systems. For the FDA, this means a significant administrative undertaking to update its vast array of documents and communications. While the change is primarily semantic, it could influence public perception and understanding of these technologies, potentially emphasizing their advanced capabilities and societal impact. The distinction between 'Super Intelligence' and 'Artificial Intelligence' might also subtly guide future policy discussions and regulatory approaches, even if the underlying technical definitions remain consistent with existing law. This move could also set a precedent for other federal agencies, leading to a broader adoption of the new terminology across the U.S. government. The order does not impose new requirements on external entities submitting information to the FDA, ensuring that industry stakeholders are not immediately burdened by the terminological change in their submissions.
What's Next?
Beginning November 16, 2026, the FDA will actively implement the new terminology, using 'Super Intelligence' and 'SI' in all new public-facing documents and communications where applicable and legally permissible. Existing guidance documents, regulations, and Federal Register notices will remain in effect as originally written, but their terminology will be conformed during subsequent substantive revisions. The FDA also plans to update its forms, electronic submission templates, databases, and web content during their normal maintenance cycles to reflect the new terms. This phased approach suggests a gradual transition rather than an immediate overhaul. Other executive departments and agencies are expected to follow suit, leading to a widespread adoption of 'Super Intelligence' and 'SI' across the federal government. The long-term impact will depend on how this new terminology influences public and legislative understanding and engagement with these technologies.
Beyond the Headlines
The introduction of 'Super Intelligence' as a preferred term over 'Artificial Intelligence' could have deeper implications beyond mere semantics. It might reflect a strategic move to differentiate the U.S. government's approach to advanced technologies, potentially signaling a focus on more sophisticated or transformative capabilities. This linguistic shift could also be an attempt to shape public and international perceptions, positioning the U.S. at the forefront of a new era of technological advancement. Ethically, the choice of 'Super Intelligence' might evoke different societal expectations and concerns compared to 'Artificial Intelligence,' potentially influencing discussions around control, safety, and the future role of these systems in society. Legally, while the Executive Order clarifies that the definition remains consistent with existing law, the new terminology could subtly influence judicial interpretations or future legislative efforts by framing the technology in a new light. This rebranding could also be a response to the evolving global landscape of AI development and regulation, aiming to carve out a distinct narrative for U.S. policy.













